JANX Janux Therapeutics, Inc. Insider Trading

RA Capital Management director bought 824,041 shares in 4 tranches for $25.3M at average $30.75, lifting stake to 10.14M shares amid 54.2% decline from 52-week high.

RA Capital Management, as director of Janux Therapeutics, executed 4 separate purchases totaling 824,041 shares for $25,342,964.88 between March 5–7, 2025, at prices ranging from $30.56 to $31.30—a blended average of $30.75. This increased the firm's holdings from 9,317,246 shares to 10,141,287 shares, a net increase of 8.8%. The timing coincides with severe recent price pressure: the stock trades 54.2% below its 52-week high and down 31.4% over the prior 30 days. While RA Capital's cross-ticker track record shows a 46.67% 90-day win rate on buys with an average 90-day return of +250.0%, this represents aggregate historical performance; at Janux specifically, its single prior purchase on 2024-10-18 returned -9.2% over 90 days, establishing 0 out of 1 well-timed buys at this ticker. The company remains unprofitable (net income of $-28,059,000.00 in the latest full year) despite 31.0% annual revenue growth, adding fundamental uncertainty to any conviction read. The large dollar scale ($25.3M) and multi-tranche execution over three trading days in a distressed price environment warrant monitoring of subsequent price action and any public commentary on the rationale.

JANX CEO David Alan sold 25,000 shares at $56.19 on 2024-12-24; stock now $54.10, down -19.1% from 52-week high.

David Alan, President and CEO of Janux Therapeutics, sold 25,000 shares (reducing his holdings from 242,054 to 217,054 shares, a 10.3% reduction) at $56.19 per share on 2024-12-24. The stock has since declined to $54.10, situating this sale near the upper range of the 52-week span (down 19.1% from the $66.84 high but up 16.6% over the prior 30 days). This marks his fifth discrete open-market sale at JANX within five weeks, with the prior four sales showing mixed near-term outcomes: two posted positive 30-day returns (+9.2% and +7.9%) while two showed negative 30-day returns (-14.0% and -12.8%). The company remains unprofitable (most recent quarter net income: $-28,059,000.00), with annual revenue declining 6.1% year-over-year, providing a backdrop of operational stress against which repeated CEO sales warrant investor scrutiny of upcoming earnings and cash-burn trajectory.

JANX CEO David Campbell sold 15,000 shares at $67.00 for $1.0M on 2024-12-03; stock now at $59.86.

Campbell David Alan, President and CEO, sold 15,000 shares at $67.00, reducing his holdings from 257.1K to 242.1K shares (a -5.8% decrease). The sale occurred near the 52-week high of $64.78, and the stock has since declined 7.6% from that peak to $59.86 current price. At JANX specifically, the CEO's 5 prior trades show mixed outcomes: recent October sales yielded negative 30-day returns of -12.8% and -14.0%, while a September sale returned +14.0%, indicating no clear pattern of timing acuity. The company's fundamentals remain challenged: latest quarterly revenue stands at $439.0K with a net loss of $28.1M, annual revenue declined -6.1%, and the firm remains unprofitable on a full-year basis with a $3.1B market cap. The timing and magnitude of this sale against deteriorating fundamentals warrant investor attention to whether the CEO is adjusting his exposure amid operational headwinds.

CEO Campbell David Alan sells 25,000 JANX shares at $51.60 blended average; stock now at $46.39, down 14.7% in 30 days.

Campbell David Alan executed two separate sales totaling 25,000 shares for $1,289,878.73 on November 25, 2024, at an average price of $51.60. The stock has declined 14.7% over the subsequent 30-day period and now trades at $46.39, placing it 28.4% below its 52-week high of $64.78. This sale represents an 8.9% reduction in the insider's holdings from 282.1K to 257.1K shares. Notably, JANX is unprofitable with a net income of $-28.1M in its most recent full fiscal year, operates on minimal quarterly revenue of $439.0K, and has experienced an annual revenue decline of 6.1% year-over-year. The insider's prior two trades at this ticker (both on 2024-10-28) posted negative 30-day returns of 12.8% and 14.0%, consistent with the recent downward price momentum.

CEO Campbell David Alan sells 25,000 JANX shares for $1,338,558.90; 3rd sale in one month as stock surges +23.2% in 30 days.

Campbell David Alan, President and CEO, executed 2 separate sales on 2024-10-28 totaling 25,000 shares (25.0K shares) for $1,338,558.90 ($1.3M), reducing his post-transaction holdings to 282,054 shares (282.1K shares) from 307,054 shares (307.1K shares). This represents his third sale in as many days—following two sales on 2024-09-27—during a period when JANX stock has gained +23.2% over 30 days and +35.0% over 90 days, reaching near its 52-week high of $64.78. The company remains unprofitable (net income $-5,959,000.00 ($-6.0M) in the latest quarter) with declining annual revenue (-6.1% year-over-year), yet the stock has appreciated significantly. Prior sales by this insider at JANX have shown positive 30-day returns (15.9%, 14.0%, 11.6%), suggesting his recent sales preceded further price appreciation rather than declines. The concentrated timing of these three sales during a sustained rally warrants close monitoring of whether this pattern reflects circumstances specific to the insider, the company, or market conditions.

RA Capital Management bought 1,200,000 shares of JANX at $44.75 ($53.7M), lifting stake to 9,317,246 shares

RA Capital Management's $53.7M purchase of 1,200,000 shares represents a substantial 14.8% increase in holdings at $44.75 per share. The transaction is material in absolute size and signals continued engagement at a director level, though context is mixed: JANX is unprofitable with $-6.0M net income on $8.9M quarterly revenue and declining annual growth (-6.1%), yet the stock has recovered 16.3% over 90 days and trades only 18.5% below its 52-week high of $64.78. Notably, RA Capital's cross-ticker track record shows a 43.75% win rate on 18 prior buys with modest 30d and 90d average returns (+224.1% and +240.6% respectively), yet this provides limited predictive value for a single-ticker positioning decision in an early-stage biotech with significant operational headwinds.

10% holder Avalon Ventures XI sold 1,673,128 shares for $77,472,371.23 across 17 transactions on Oct 16–18

Avalon Ventures XI, a 10% owner of Janux Therapeutics, executed 17 separate sales totaling 1,673,128 shares for $77,472,371.23, reducing holdings by 44.2% from 3,788,501 shares to 2,115,373 shares post-transaction. The blended average sale price of $46.30 falls below the current price of $50.03, and 22.8% below the 52-week high of $64.78. This represents a material reduction in the holder's stake in an unprofitable biotech company (quarterly net income of $-5,959,000.00 and annual revenue decline of -6.1%), occurring after five recent sale transactions in late September 2024. The concentration of sales on October 18 at substantially lower price points ($44.75 in particular, representing the majority share volume) alongside earlier sales at higher prices ($49.69–$51.18) suggests execution across multiple price levels over the filing window rather than a single-moment transaction.

10% Owner Avalon Ventures XI sells 307,779 shares (307.8K shares) for $14,452,393.76 ($14.5M) across 14 transactions, reducing stake by 97.8%.

Avalon Ventures XI, a 10% owner, executed 14 separate sales totaling 307,779 shares (307.8K shares) for $14,452,393.76 ($14.5M) on 2024-09-26 through 2024-09-30, with a blended average price of $46.96. This represents a near-complete exit, reducing holdings by 97.8% from 314,666 shares (314.7K shares) to 6,887 shares (6.9K shares). The timing is notable: the sales occurred 14–29 days before the current price of $45.43, which stands 29.9% below the 52-week high of $64.78. Across the insider's cross-ticker track record, prior sells averaged a 90-day return of -14.2% with a 100% well-timed rate, though this comparison must be weighted against the absence of measurable same-ticker outcomes at JANX (5 prior trades from 2024-09-10 through 2024-09-12 have no yet-measurable 30d or 90d results). The company's fundamentals show an unprofitable state over its most recent full fiscal year, with a latest-quarter net income of -$5,959,000.00 (-$6.0M) against revenue of $8,897,000.00 ($8.9M), alongside negative annual revenue growth of -6.1%.

JANX CEO Campbell sold 25,000 shares for $1.2M at $46.31 avg; retains 307.1K shares

Campbell David Alan, President and CEO, executed 3 separate sales totaling 25,000 shares for $1,157,641.43 on 2024-09-27, reducing his holdings by 7.5% while retaining 307.1K shares. The blended average price of $46.31 is closely aligned with the current price of $46.25, indicating execution near current market levels. Against the company's fundamental backdrop—unprofitable full-year performance with net income of $-5,959,000.00 and annual revenue decline of 6.1%—a CEO equity reduction of this scale is notable for its timing relative to operational headwinds. The stock trades -28.6% from its 52-week high of $64.78, having risen +10.4% over the prior 90 days; the sale occurs within this recent upward move but well below prior peaks.

Chief Business Officer sold 50,000 JANX shares ($2.3M) at $45.96; stock down 28.6% from 52-week high; company unprofitable.

Meyer Andrew Hollman, Chief Business Officer, sold 50,000 shares (representing a 42.5% reduction of his pre-transaction holdings of 117,592 shares) on 2024-09-27 at $45.96 per share, generating $2,297,755.00 in proceeds. The sale occurred while the stock trades at $46.25, down 28.6% from its 52-week high of $64.78, and reflects a company with negative fundamentals: quarterly revenue of $8,897,000.00 paired with a quarterly net loss of $5,959,000.00, annual revenue decline of 6.1%, and full-year unprofitability. The substantial reduction in holdings by a senior executive at a loss-making enterprise with declining top-line growth presents a material cash realization event worth monitoring for its signal regarding near-term business trajectory or capital allocation priorities.